Pharmaceutical Industry Sector Study proposed by ODE
28 March 2011
Read by 1535 persons
The pharmaceutical industry has undergone profound structural changes over the last decade.
Indeed, at the international level, emerging countries are gradually stealing the spotlight from major powers, thanks to a growing middle class that, despite low social coverage, is able to consume more medicines.
At the same time, the widening deficits of payers influences the behavior of States and operators, who are now more oriented towards more diversified strategies: development of biotechnologies, use of generics, focus on specific therapeutic classes and niches, and acquisition or merger with other entities.
At the national level, and despite the young age of this industry, Morocco manages to produce nearly 65% of its medicine needs and exports 10% of its production, mainly to African countries.
This dynamism is largely due to the constant support of the state and the enthusiasm of operators. To this end, and aware of the low consumption of medicines and their high cost relative to citizens' incomes, the Government has undertaken a reform process, placing generics at the heart of its strategy.
Operators, for their part, are competing with strategies to stand out and improve their margins. While some are establishing themselves in Africa, others are opting for the acquisition of new factories or even deciding to go public to finance their expansion.
In terms of financial performance, the turnover of national operators has recorded an average annual growth of 13.5% over the last 4 years. This is mainly due to the introduction of the compulsory health insurance system and the marketing of generics. However, some laboratories suffer from poor debt recovery management, leading to high "passive" cash flow.
To access the electronic version of the study, register free of charge on the ODE website, by clicking here
Posted on March 28, 2011
Ode.ma
Indeed, at the international level, emerging countries are gradually stealing the spotlight from major powers, thanks to a growing middle class that, despite low social coverage, is able to consume more medicines.
At the same time, the widening deficits of payers influences the behavior of States and operators, who are now more oriented towards more diversified strategies: development of biotechnologies, use of generics, focus on specific therapeutic classes and niches, and acquisition or merger with other entities.
At the national level, and despite the young age of this industry, Morocco manages to produce nearly 65% of its medicine needs and exports 10% of its production, mainly to African countries.
This dynamism is largely due to the constant support of the state and the enthusiasm of operators. To this end, and aware of the low consumption of medicines and their high cost relative to citizens' incomes, the Government has undertaken a reform process, placing generics at the heart of its strategy.
Operators, for their part, are competing with strategies to stand out and improve their margins. While some are establishing themselves in Africa, others are opting for the acquisition of new factories or even deciding to go public to finance their expansion.
In terms of financial performance, the turnover of national operators has recorded an average annual growth of 13.5% over the last 4 years. This is mainly due to the introduction of the compulsory health insurance system and the marketing of generics. However, some laboratories suffer from poor debt recovery management, leading to high "passive" cash flow.
To access the electronic version of the study, register free of charge on the ODE website, by clicking here
Posted on March 28, 2011
Ode.ma
